HOUSTON, Dec. 1, 2020 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a…
View More Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066
Home »
Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 29, 2020– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics…
View More Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
Iran announces record 337 virus deaths in single day
Iran on Monday announced 337 deaths from the novel coronavirus, a record high for a…
View More Iran announces record 337 virus deaths in single day
Imbrium Therapeutics Announces FDA Orphan Drug Designation for Tinostamustine for The Treatment of T-Cell Prolymphocytic Leukemia
STAMFORD, Conn. – March 28, 2019 – Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and…
View More Imbrium Therapeutics Announces FDA Orphan Drug Designation for Tinostamustine for The Treatment of T-Cell Prolymphocytic Leukemia
Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305
STAMFORD, Conn., Dec. 21, 2018 (GLOBE NEWSWIRE) — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company…
View More Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305